دورية أكاديمية
Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System.
| العنوان: | Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System. |
|---|---|
| المؤلفون: | Elsallab M; Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, MA.; Cellular Immunotherapy Program, Mass General Cancer Center, and Department of Medicine, Harvard Medical School, Boston, MA., Ellithi M; Fred & Pamela Buffett Cancer Center, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE., Lunning MA; Fred & Pamela Buffett Cancer Center, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE., D'Angelo C; Fred & Pamela Buffett Cancer Center, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE., Ma J; Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE., Perales MA; Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, New York, NY., Frigault M; Cellular Immunotherapy Program, Mass General Cancer Center, and Department of Medicine, Harvard Medical School, Boston, MA., Maus MV; Cellular Immunotherapy Program, Mass General Cancer Center, and Department of Medicine, Harvard Medical School, Boston, MA. |
| المصدر: | Blood [Blood] 2024 May 16; Vol. 143 (20), pp. 2099-2105. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2021- : [New York] : Elsevier Original Publication: New York, Grune & Stratton [etc.] |
| مواضيع طبية MeSH: | Neoplasms, Second Primary*/etiology , Neoplasms, Second Primary*/therapy , Neoplasms, Second Primary*/epidemiology , United States Food and Drug Administration* , Immunotherapy, Adoptive*/adverse effects , Adverse Drug Reaction Reporting Systems*, Humans ; United States/epidemiology ; Male ; Receptors, Chimeric Antigen/immunology ; Female ; Middle Aged ; Adult ; Aged |
| مستخلص: | Abstract: Second primary malignancies were reported in 536 of 12 394 (4.3%) adverse event reports following chimeric antigen receptor T-cell therapies in the Food and Drug Administration Adverse Event Reporting System. Myeloid and T-cell neoplasms were disproportionately more frequently reported, warranting further follow-up. (© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.) |
| تواريخ الأحداث: | Date Created: 20240314 Date Completed: 20240516 Latest Revision: 20240516 |
| رمز التحديث: | 20240516 |
| DOI: | 10.1182/blood.2024024166 |
| PMID: | 38483155 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1528-0020 |
|---|---|
| DOI: | 10.1182/blood.2024024166 |